source
- FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimabThe U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
- FDA unveils Global Reliance Disclosure Program to speed international drug approvalsThe FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…